| Literature DB >> 31411057 |
Khalil Choucair1, Joseph R Duff1, Christine S Cassidy1, Mary T Albrethsen1, Jesse D Kelso1, Amanda Lenhard1, Hannah Staats1, Rayna Patel1, F Charles Brunicardi1, Lance Dworkin1, John Nemunaitis1,2.
Abstract
Natural killer (NK) cells lead immune surveillance against cancer and early elimination of small tumors. Owing to their ability to engage tumor targets without the need of specific antigen, the therapeutic potential of NK cells has been extensively explored in hematological malignancies. In solid tumors, however, their role in the clinical arena remains poorly exploited despite a broad accumulation of preclinical data. In this article, we review our current knowledge of NK cells' biology, and highlight the challenges facing NK cell antitumor strategies in solid tumors. We further summarize the abundant preclinical attempts at overcoming these challenges, present past and ongoing clinical trial data and finally discuss the potential impact of novel insights on the development of NK cell-based therapies.Entities:
Keywords: CAR-NK; NK cells; adoptive transfer; cancer stem cells; clinical trials; immune escape; immune surveillance; receptor signaling modulation; solid tumors
Mesh:
Substances:
Year: 2019 PMID: 31411057 DOI: 10.2217/fon-2019-0116
Source DB: PubMed Journal: Future Oncol ISSN: 1479-6694 Impact factor: 3.404